| Literature DB >> 28421817 |
Shinya Ohkouchi1,2, Keiichi Akasaka3,4, Toshio Ichiwata5, Shu Hisata1, Hideya Iijima6, Toshinori Takada3, Hiroki Tsukada7, Hideaki Nakayama8, Jun-Ichi Machiya9, Toshiya Irokawa2, Hiromasa Ogawa2, Yoko Shibata10, Masakazu Ichinose1, Masahito Ebina11, Toshihiro Nukiwa12, Hajime Kurosawa2, Koh Nakata13, Ryushi Tazawa13.
Abstract
Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare disease characterized by the excessive accumulation of surfactant proteins within the alveolar spaces and by higher titers of autoantibodies to granulocyte-macrophage colony-stimulating factor (GM-CSF) in the serum and bronchoalveolar lavage fluid. The antibodies inhibit the maturation and phagocytosis of alveolar macrophages. Although the standard therapy for aPAP has been whole-lung lavage (WLL), this procedure is invasive and needs to be repeated for several years. GM-CSF inhalation therapy is a new procedure for treating aPAP and can induce remission with less invasiveness, although it is generally less effective in severe cases. We evaluated five cases with remarkable improvement by using sequential GM-CSF inhalation therapy after WLL; however, the treatment failed when this therapy preceded WLL. Therefore, sequential GM-CSF inhalation after WLL may reinforce the efficiency of WLL in patients with severe aPAP.Entities:
Keywords: autoimmune pulmonary alveolar proteinosis; granulocyte-macrophage colony-stimulating factor; inhalation; whole-lung lavage
Mesh:
Substances:
Year: 2017 PMID: 28421817 DOI: 10.1513/AnnalsATS.201611-892BC
Source DB: PubMed Journal: Ann Am Thorac Soc ISSN: 2325-6621